The goal of this CORE is to provide investigators in this SPORE with high quality patient data, DNA, RNA, serum, and breast tissues from breast cancer patients and normal control patients, and to make these resources available for future translational studies. The activities of the CORE will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible in the materials that are provided. The acquisition of human biospecimens and subsequent cellular and molecular analysis of those specimens within the context of patient data are key to many translational studies of cancer. The Mayo Clinic has a strong tradition of biospecimen acquisition and centralized patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. Currently, the Biospecimen and Accessioning (BAP) and the Tissue and Cell Molecular Analysis (TACMA) Shared Resources of the Mayo Clinic Cancer Center provide normal and neoplastic human tissues for cancer research at Mayo, and are resources of expertise, collaborative support, and service for pathology, immunohistochemistry, laser capture microdissection, tissue microarray preparation, and nucleic acid extraction. The Biospecimens and Patient Registry Core of this SPORE will be integrated with the existing Shared Resources in order to provide a coordinated, centralized, dedicated program for procuring, processing, and assessing biospecimens and patient data from breast cancer patients and to provide these specimens for research projects within this SPORE and to other investigators with translational research projects. This CORE will interact closely with the Biostatistics Core of this SPORE to integrate data into a single database and to provide specimens that meet the statistical requirements for translational research projects supported by this SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-03
Application #
7550582
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$231,366
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Augusto, Bianca; Kasting, Monica L; Couch, Fergus J et al. (2018) Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. J Immigr Minor Health :
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Fasching, Peter A; Loibl, Sibylle; Hu, Chunling et al. (2018) BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 36:2281-2287
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Augusto, Bianca M; Lake, Paige; Scherr, Courtney L et al. (2018) From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Community Genet 9:209-215
Tu, Xinyi; Kahila, Mohamed M; Zhou, Qin et al. (2018) ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Mol Cancer Ther 17:2462-2472
Athreya, Arjun P; Gaglio, Alan J; Cairns, Junmei et al. (2018) Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer. IEEE Trans Nanobioscience 17:251-259

Showing the most recent 10 out of 473 publications